RecruitingRecruiting
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency
NCT04789148 · Massachusetts General Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency - A Pilot Study
About this study
This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repeated dose substudy of intranasal oxytocin 6 IU or placebo (Part B).
Following a screening visit to determine eligibility, participants will return for three main study visits in Part A. During the main study visits, study participants will receive either oxytocin or placebo, followed by assessments of emotional behavior.
In Part A, thirty participants will be equally randomized to one of six possible groups:
1. 6 IU oxytocin - 24 IU oxytocin - placebo
2. 6 IU oxytocin - placebo - 24 IU oxytocin
3. 24 IU oxytocin - 6 IU oxytocin - placebo
4. 24 IU oxytocin - placebo - 6 IU oxytocin
5. placebo - 6 IU oxytocin - 24 IU oxytocin
6. placebo - 24 IU oxytocin - 6 IU oxytocin
Following completion of the Part A crossover portion of the study, in Part B participants may also choose to continue participation in an optional, randomized, double-blind, placebo-controlled substudy of intranasal oxytocin 6 IU or placebo three times a day for two weeks, followed by assessments of emotional behavior.
Eligibility criteria
Inclusion Criteria:
* Age 18 and above
* Arginine-vasopressin deficiency
* Normal FT4
* Normal serum/plasma sodium
* Stable hormone replacement
Exclusion Criteria:
* Active substance use disorder within the last 6 months
* History of psychosis
* Suicidal behavior and/or active suicidal ideation with plan and/or intent, e.g., suicidal ideation of type 4 or type 5 as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS), in the last month
* Medication changes that could interfere with study procedures or endpoints per study physician discretion
* History of chronic nasal obstruction or local pathology in nostril pathway which, in the opinion of the investigator, would prevent appropriate nasal administration of the study drug.
* History of clinically relevant ventricular arrhythmias, coronary heart disease, and hypertrophic cardiomyopathy
* History of chronic kidney disease stage III and above
* History of liver cirrhosis
* Pregnancy or breastfeeding within the last 8 weeks
* Unwilling to use a medically acceptable form of contraception throughout the study period (female of child-bearing potential only)
* Any significant illness, condition, drug or medical device that the Investigator determines could interfere with study participation, data collection, or safety
Study design
Enrollment target: 40 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2025-09-10
Estimated completion: 2027-06
Last updated: 2026-10-26
Interventions
Drug: Intranasal Oxytocin (IN-OXT) 6 IU single doseDrug: Intranasal Oxytocin (IN-OXT) 6 IU repeat doseDrug: Placebo repeat doseDrug: Intranasal Oxytocin (IN-OXT) 24 IU single doseDrug: Placebo single dose
Primary outcomes
- • Dot-probe task - anxious behavior between low dose oxytocin and placebo (20 minutes following intervention at each main visit)
Sponsor
Elizabeth Austen Lawson · other
With: Tonix Pharmaceuticals, Inc.
Contacts & investigators
ContactElizabeth A Lawson, MD, MMSc · contact · ealawson@mgh.harvard.edu · (617) 726-3870
ContactElisa Asanza, MSN, MPH · contact · easanza@mgh.harvard.edu · 617-726-3870
InvestigatorElizabeth A Lawson, MD, MMSc · principal_investigator, Massachusetts General Hospital
All locations (1)
Massachusetts General Hospital, Neuroendocrine UnitRecruiting
Boston, Massachusetts, United States